Imagine a world where organ transplants are no longer a race against time, and life-sustaining technology is as portable as a backpack. This is the bold vision driving Science Corporation, a brain-computer interface startup founded by former Neuralink president Max Hodak, to venture into the realm of organ preservation. But here's where it gets controversial: can we truly revolutionize this field, making it accessible and affordable, or will it remain a privilege for the few?
Science, headquartered in Alameda, California, is tackling the limitations of current perfusion systems—those clunky, expensive machines that keep organs alive outside the body for transplant or as a temporary lifeline for critically ill patients. Their goal? To create a smaller, more portable, and cost-effective solution that could transform the way we approach organ preservation and life support.
Until recently, Science focused on neural interfaces and vision restoration, including a groundbreaking 'biohybrid' interface using living neurons to connect with the brain. Their retinal implant, acquired from French startup Pixium Vision in 2024, has already restored partial vision to patients with advanced macular degeneration, allowing them to read letters and words. This success positions Science ahead of Elon Musk’s Neuralink in the race to combat vision loss.
But why the sudden shift to organ preservation? Hodak’s inspiration came from a heartbreaking case: a 17-year-old boy in Boston with cystic fibrosis, whose life was sustained by an extracorporeal membrane oxygenation (ECMO) machine while awaiting a lung transplant. After two months, complications made him ineligible for the transplant, and the ethical dilemma of keeping him on the costly, short-term ECMO system ultimately led to his tragic death.
ECMO machines, while lifesaving, are prohibitively expensive—costing thousands of dollars per day—and require constant monitoring in a hospital setting. Their resource-intensive nature limits their availability, leaving many without access. Hodak poses a thought-provoking question: What if we could create a system so portable that a patient could carry it home, or even transport organs as easily as checking luggage on a flight?
And this is the part most people miss: beyond ECMO, even perfusion systems designed for organ transplants are outrageously priced. Companies like TransMedics offer organ care systems costing upwards of $250,000, plus tens of thousands per use, often relying on private jets for long-distance organ transport. Science aims to disrupt this status quo with a prototype that’s not only more affordable but also smarter, featuring real-time monitoring and automatic adjustments—a stark contrast to the manual controls of current ECMO machines.
A small team at Science has already built a perfusion system that keeps rabbit kidneys viable outside the body for up to 48 hours, with plans to extend this to a month by next spring. For context, human kidneys stored on ice typically last 24 to 36 hours, while existing perfusion machines can stretch this to four days. Hodak’s vision for Science, now boasting 170 employees, has always included organ preservation, but the company needed time to build the foundation for this ambitious leap.
Their prototype incorporates integrated sensors for real-time monitoring of blood oxygenation, flow rate, pressure, and temperature, along with a modular design to support various organs and applications. This closed-loop system automates adjustments, eliminating the need for constant manual intervention.
Science won’t be alone in this endeavor; they’ll compete with other companies developing automated perfusion systems. While these devices are becoming more common, they remain costly and often require specialized staff. Hodak’s goal is to bridge the gap between what the technology can do and how it’s actually used, making it accessible to more people.
But here’s the question for you: Is this a realistic goal, or will the complexities of healthcare systems and profit-driven industries keep organ preservation technology out of reach for most? Hodak believes that success in this field could shift us from conventional medicine’s challenges to a future of 'swappable parts,' where organ preservation is as routine as any other medical procedure. What do you think? Let’s spark a conversation in the comments.
